Julien Coste
Director of Finance/CFO chez INTRASENSE
Postes actifs de Julien Coste
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| INTRASENSE | Chief Administrative Officer | - | - |
| Director of Finance/CFO | - | - | |
Biovertis AG
 Biovertis AG Pharmaceuticals: MajorHealth Technology Biovertis AG operates as a clinical stage pharmaceutical company. It develops small molecule drugs against proprietary microbial antigens. The firm discovers and develops antimicrobial drugs for infections caused by antibiotic-resistant bacterial pathogens. The company was founded by Erich Felber, Uwe von Ahsen, and Alexander Ullrich von Gabain in 2003 and is headquartered in Vienna, Austria. | Chief Executive Officer | 22/08/2018 | - |
Historique de carrière de Julien Coste
Anciens postes connus de Julien Coste
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| DEINOVE | Chief Administrative Officer | 31/07/2012 | - |
| Director of Finance/CFO | 31/07/2012 | - | |
| Public Communications Contact | 31/07/2012 | - | |
Neuro3D SA
 Neuro3D SA Pharmaceuticals: OtherHealth Technology Neuro3d SA develops pharmaceutical products to treat the central nervous system. Neuro3d has a full pipeline of innovative compounds with new mechanisms of action that have the potential to overcome the limitations of current drug therapies. It leads compound, the atypical antipsychotic ocaperidone, is being investigated in two international double-blind Phase II trials for treatment of schizophrenia. The company was founded in November 2000 and is headquartered in Mulhouse, France. | Chief Administrative Officer | - | - |
| Director of Finance/CFO | - | - |
Formation de Julien Coste
| Université Paris Dauphine-PSL | Graduate Degree |
| Ecole Superieure Commerce Grenoble Business School | Undergraduate Degree |
Statistiques
Internationale
| France | 6 |
| Autriche | 2 |
Opérationnelle
| Chief Administrative Officer | 3 |
| Director of Finance/CFO | 3 |
| Public Communications Contact | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 3 |
| Technology Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INTRASENSE | Technology Services |
| Entreprise privées | 3 |
|---|---|
Neuro3D SA
Neuro3D SA Pharmaceuticals: OtherHealth Technology Neuro3d SA develops pharmaceutical products to treat the central nervous system. Neuro3d has a full pipeline of innovative compounds with new mechanisms of action that have the potential to overcome the limitations of current drug therapies. It leads compound, the atypical antipsychotic ocaperidone, is being investigated in two international double-blind Phase II trials for treatment of schizophrenia. The company was founded in November 2000 and is headquartered in Mulhouse, France. | Health Technology |
Biovertis AG
Biovertis AG Pharmaceuticals: MajorHealth Technology Biovertis AG operates as a clinical stage pharmaceutical company. It develops small molecule drugs against proprietary microbial antigens. The firm discovers and develops antimicrobial drugs for infections caused by antibiotic-resistant bacterial pathogens. The company was founded by Erich Felber, Uwe von Ahsen, and Alexander Ullrich von Gabain in 2003 and is headquartered in Vienna, Austria. | Health Technology |
Deinove SA
 Deinove SA BiotechnologyHealth Technology Deinove SA is a biotechnology company, which engages in the development of new-generation anti-infective antibiotics and bioactives. Its portfolio include Phy-N-Resist and HEBELYS. The company was founded by Philippe Pouletty and Miroslav Radman on October 11, 2006 and is headquartered in Grabels, France. | Health Technology |
- Bourse
- Insiders
- Julien Coste
- Expérience
